

BGI Genomics empowers Brunei's national cervical cancer prevention programme

18 January 2025 | News

Supporting the WHO's global strategy of cervical cancer elimination by 2030



The Brunei Ministry of Health (MoH), in partnership with Borneo Genomics Innovation (BGIB), a joint venture of China's BGI Genomics in Brunei, has launched the National Cervical Cancer Prevention and Control Programme along with the 2025 National Guideline. The programme aims to enhance early detection and eliminate cervical cancer across Brunei.

The updated guideline highlights that HPV DNA-based testing as a primary tool for early detection offers a more accurate and reliable method compared to cytology. With royal family authorisation and MoH leadership, this national project supports the WHO's global strategy of cervical cancer elimination by 2030 and demonstrates Brunei's dedication to local and global health goals.

This programme incorporates a national HPV DNA screening initiative for all women aged 25 to 65. The HPV self-sampling kits are available at 32 clinics, four hospitals, and three gynecology wards in Brunei's four districts.

As another public health collaboration between BGI Genomics and the Brunei government, this initiative marks the transformation of BGI Genomics' first Huo-Yan Lab built in an ASEAN country.